02 August 2018-Bucharest, Romania. People waiting and watching in the public park Herastrau for the movie to start on the projection screen of the open air cinema

EYLEA® (aflibercept) and Soliris® (eculizumab) IPR Updates

Start
On December 8, 2023, the PTAB instituted three of Samsung Bioepis’s pending IPRs against Alexion’s Soliris® (eculizumab), IPR2023-00933, IPR2023-00998, and IPR2023-00999. The challenged patents include composition of matter, formulation, and method of treatment claims.  Samsung Bioepis filed two additional IPRs in June, IPR2023-01069 and IPR2023-01070, that are awaiting institution decisions….
By: Venable LLP
Previous Story

The EU Reaches a Political Agreement on the AI Act

Next Story

Akira, again: The ransomware that keeps on taking